CardiacAssist gets US OK for TandemHeart PTVA (percutaneous transseptal ventricular assist) technology:
This article was originally published in Clinica
Executive Summary
CardiacAssist can now market in the US its TandemHeart percutaneous transseptal ventricular assist (PTVA) system for short-term circulatory support, after gaining FDA 510(k) clearance for the product's final component: the transseptal cannula. The TandemHeart PTVA device was previously CE-marked for sale in Europe in 2000. It can be used to support critically ill patients with heart failure and cardiogenic shock. The system is currently being compared with conventional intra aortic balloon pump therapy in a cardiogenic shock trial in the US, says the Pittsburgh, Pennsylvania firm.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.